copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Hydrocortisone in Severe Community-Acquired Pneumonia | NEJM We conducted the Community-Acquired Pneumonia: Evaluation of Corticosteroids (CAPE COD) trial to evaluate whether early treatment with hydrocortisone reduced mortality at 28 days among
Hydrocortisone in Severe Community-Acquired Pneumonia Among patients with severe community-acquired pneumonia being treated in the ICU, those who received hydrocortisone had a lower risk of death by day 28 than those who received placebo
CAPE COD - The Bottom Line In patients with severe community acquired pneumonia (CAP) does the use of hydrocortisone compared to a placebo reduce 28-day mortality? The recently published trial by Meduri et al showed no 60-day mortality benefit with the use of methylprednisolone in severe CAP
Current corticosteroid therapeutic strategy for community-acquired . . . In the ESCAPe trial, participants received 40 mg of methylprednisolone (mPSL) daily for a fixed duration of 7 days, whereas in the CAPE COD trial, participants received hydrocortisone at a total daily dose of 200 mg, administered for 4 or 7 days depending on their clinical response
Hydrocortisone in Severe Community-Acquired Pneumonia | NEJM To the Editor: In their article on the Community-Acquired Pneumonia: Evaluation of Corticosteroids (CAPE COD) trial, Dequin et al (May 25 issue) 1 report an almost 50% lower 28-day
Steroids harmed community-acquired pneumonia patients? (REMAP-CAP) In 2020, REMAP-CAP added to the signal that steroids (hydrocortisone) appeared to be beneficial in patients with severe Covid pneumonia Dexamethasone soon became standard therapy for severe Covid, based on the frequentist RECOVERY trial
Steroids in severe community-acquired pneumonia: dangerous, worthless . . . The CAPE COD trial is a multicenter, double-blind, placebo-controlled trial in 31 French ICUs evaluating 200 mg day infusion of hydrocortisone for 8 or 14 days with a planned taper in patients admitted in ICU with severe non-viral CAP